ASCO26: Data highlights test benefit in breast cancer treatment planning and earlier detection

While emerging data on biomarkers and patient-reported outcomes increasingly inform oncology and psychiatry practice, the evidence base for medical cannabis in these domains remains fragmented and difficult to integrate into standard clinical decision-making. The relationship between cannabis use and cancer risk, treatment efficacy, and psychiatric comorbidities involves multiple confounders including dose, frequency, cannabinoid composition, route of administration, and individual genetic factors that are rarely controlled for in observational studies. Healthcare providers should be cautious about extrapolating preliminary findings into routine practice without robust comparative effectiveness data and should counsel patients that cannabis is not an established adjunct to evidence-based cancer detection or psychiatric treatment at this time. However, given the prevalence of patient interest and use, clinicians caring for patients with cancer or psychiatric conditions should ask directly about cannabis use, document it clearly, and remain informed about emerging evidence while acknowledging the current gaps to patients honestly. A measured approach involves staying updated